{"nctId":"NCT00566228","briefTitle":"Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma","startDateStruct":{"date":"2007-12"},"conditions":["Lymphoma"],"count":122,"armGroups":[{"label":"Immunologic autograft engineering","type":"EXPERIMENTAL","interventionNames":["Procedure: autologous hematopoietic stem cell transplantation","Procedure: leukapheresis"]},{"label":"Standard autograft collection","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: autologous hematopoietic stem cell transplantation","Procedure: leukapheresis"]}],"interventions":[{"name":"autologous hematopoietic stem cell transplantation","otherNames":[]},{"name":"leukapheresis","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of diffuse large cell lymphoma\n\n  * Low-grade non-Hodgkin lymphoma transformed to diffuse large cell lymphoma allowed\n* Candidate for with autologous peripheral blood stem cell transplantation\n\n  * Not requiring bone marrow harvest to collect stem cells\n  * No chemotherapy with filgrastim ( G-CSF) or mobilization study drug (i.e., AMD3100) needed for mobilization of stem cells\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-1\n* Cardiac and pulmonary status sufficient to undergo apheresis and stem cell transplantation\n* Negative pregnancy test\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* HIV negative\n* No active uncontrolled infection requiring antibiotic treatment\n* No comorbid condition which, in view of the investigators, renders the patient at high risk from treatment complications\n* Willing to provide all research blood samples as required by the protocol\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 4 weeks since prior chemotherapy (rituxan is not considered chemotherapy for the purpose of this study)\n* More than 4 weeks since prior experimental therapy\n* No concurrent enrollment on another experimental protocol during the mobilization phase\n* No concurrent participation in any autologous stem cell transplantation study that is not using the standard conditioning regimens for lymphomas","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Median Progression-free Survival","description":"Progression free survival (PFS) was defined as the time from the date of infusion to disease progression, relapse, or death from any cause. Patients alive without disease progression or relapse were censored at their last disease evaluation or at their secondary primary cancer diagnosis, whichever occurred first. Criteria for Relapsed Disease: Appearance of any new lesion or increase by ≥50% in the size of previously involved sites, ≥50% increase in greatest diameter of any previously identified node \\>1.0 cm in its short axis or in the sum of the products of diameters (SPD) of more than one node. Criteria for Progressive Disease: ≥50% increase from nadir in the SPD of any previously identified abnormal node or ALC for partial remissions or non-responders, Appearance of any new lesion (≥ 2x2 cm). A log rank test was used to assess whether PFS differed with respect to apheresis collection method.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival Rate at 1 Year","description":"Progression-free survival rate (percentage) at one year is defined as 100 times the number of patients who have not progressed, relapsed and/or died divided by the total number of evaluable patients in each arm. Criteria for Relapsed Disease: Appearance of any new lesion or increase by ≥50% in the size of previously involved sites, ≥50% increase in greatest diameter of any previously identified node \\>1.0 cm in its short axis or in the SPD of more than one node. Criteria for Progressive Disease: ≥50% increase from nadir in the SPD of any previously identified abnormal node or ALC for partial remissions or non-responders, Appearance of any new lesion (≥ 2x2 cm).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":null},{"groupId":"OG001","value":"65.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival Rate at 2 Years","description":"Progression-free survival rate (percentage) at two years is defined as 100 times the number of patients who have not progressed, relapsed and/or died divided by the total number of evaluable patients in each arm. Criteria for Relapsed Disease: Appearance of any new lesion or increase by ≥50% in the size of previously involved sites, ≥50% increase in greatest diameter of any previously identified node \\>1.0 cm in its short axis or in the SPD of more than one node. Criteria for Progressive Disease: ≥50% increase from nadir in the SPD of any previously identified abnormal node or ALC for partial remissions or non-responders, Appearance of any new lesion (≥ 2x2 cm).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.9","spread":null},{"groupId":"OG001","value":"65.4","spread":null}]}]}]},{"type":"SECONDARY","title":"One-year Overall Survival Rate","description":"Overall survival (OS) was defined at the time from infusion to death from any cause. The one-year OS rate is defined as the percentage of patients who are still alive after one year. A log rank test was used to assess whether OS differed with respect to apheresis collection method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null},{"groupId":"OG001","value":"83.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Time to Absolute Lymphocyte Count Engraftment","description":"The time to absolute lymphocyte count (ALC) engraftment will be evaluated and compared between the two arms, where time to ALC engraftment is defined as the time from transplant to the time they achieve ALC \\> 500.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Number of CD34 Cells/kg Infused","description":"Five (5) to seven (7) days after patient received granulocyte-colony stimulating factor and reached a peripheral CD34 count of 10 cells/microliter or greater, stem cell collection began. Apheresis collections were to be performed daily. At least 2 x 10\\^6 CD34 cells/kg were to be collected. Additional collections were at the discretion of the transplantation team. The median number of CD34 cells/kg infused are reported for each arm below.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Evaluation and Comparison of Immunologic Recovery Within and Between the Arms by Assessing the Quantitative and Functional Immune Effector Cells (T, B, or NK Cells) From the Apheresis Product","description":"Evaluation and comparison of immunologic recovery within and between the arms by assessing the quantitative and functional immune effector cells (T, B, or NK cells) from the apheresis product","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":57},"commonTop":["Bruising","Peripheral sensory neuropathy","Platelet count decreased","Hemoglobin decreased","Injection site reaction"]}}}